Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome,

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2017-06, Vol.96 (6), p.887-894
Hauptverfasser:	Braulke, Friederike, Schulz, Xenia, Germing, Ulrich, Schuler, Esther, Platzbecker, Uwe, Nolte, Florian, Hofmann, Wolf-Karsten, Giagounidis, Aristoteles, Götze, Katharina, Lübbert, Michael, Schlenk, Richard F., Schanz, Julie, Bacher, Ulrike, Ganser, Arnold, Büsche, Guntram, Letsch, Anne, Schafhausen, Philippe, Bug, Gesine, Brümmendorf, Tim H., Haas, Rainer, Trümper, Lorenz, Shirneshan, Katayoon, Haase, Detlef
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adult Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antigens, CD34 - blood Chromosome Banding Chromosome Deletion Chromosomes, Human, Pair 5 - genetics Disease-Free Survival Female Germany Hematology Humans In Situ Hybridization, Fluorescence Karyotyping Leukemia, Myeloid - diagnosis Leukemia, Myeloid - genetics Leukocytes, Mononuclear - metabolism Male Medicine Medicine & Public Health Middle Aged Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics Oncology Original Article Prognosis Thalidomide - analogs & derivatives Thalidomide - therapeutic use Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome,
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-017-2983-0